1 option
Drug Pricing Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement
ProQuest Congressional Research Digital Collection: Part C (2011 forward) Available online
View online- Format:
- Book
- Government document
- Author/Creator:
- United States. Government Accountability Office
- Language:
- English
- Subjects (All):
- Drugs.
- Government productivity.
- Manufactures.
- Physical Description:
- 1 online resource
- Contained In:
- ProQuest U.S. Congressional Research Digital Collection
- Place of Publication:
- [United States] [publisher not identified] 2011
- Summary:
- Report examining extent to which covered entities generate Health Resources and Services Administration (HRSA) 340B drug pricing program revenue and factors affecting revenue generation, reviewing how manufacturers' distribution of drugs at 340B program prices affects covered entities or non-340B providers' access to drugs, and evaluating HRSA oversight of 340B program
- Notes:
- Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed Feb. 2013). Reuse except for individual research requires license from ProQuest, LLC
- Vendor supplied data
- Other Format:
- Microfiche version United States. Government Accountability Office. Drug Pricing:. 2011 J942-423
- Publisher Number:
- CMP-2011-GAO-0418
- Access Restriction:
- Restricted for use by site license
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.